Asklepios BioPharmaceutical (AskBio), a clinical stage gene therapy company in Research Triangle Park, has acquired BrainVectis, a French company that is developing a potential gene therapy for Huntington’s disease, a fatal genetic disease of the brain.
Read More
Don Haut, PhD, who previously served as CBO at Sherlock Biosciences and Histogenics, is taking on the role at the clinical-stage adeno-associated virus (AAV) gene therapy company based in RTP.
Read More
A search of data maintained by the NC Biotechnology Center and the UNC Population Center finds that females today account for just 5% of the CEOs, founders and/or presidents of the state’s 735-plus life science companies. Here’s a look inside the numbers.
Read More
Angelman syndrome is caused by the loss of function of the UBE3A gene. The disorder occurs in approximately one in 15,000 people, or about 500,000 individuals worldwide, and there is currently no cure, according to Angelman Syndrome Foundation.
Read More
Here’s our latest roundup of the latest headlines from Triangle area tech and life science companies.
Read More
The AskFirst addition comes just two months after AskBio announced a collaboration with SQZ that will open the doors for new genetic treatments by combining proprietary cell and gene therapy platform technologies.
Read More
AskBio, a gene therapy company based in RTP, will pay up to $240 million in upfront and milestone payments for a license to use gene therapy technology from Massachusetts-based Selecta Biosciences as part of a regime to treat Pompe disease.
Read More
After more than two decades of game-changing accomplishments in the life science world, Sheila Mikhail has been “discovered.”
Read More
AskBio, PPD, Novan, RedHill, Mercury Gate, Percona are all making news. Here are the headlines.
Read More
